Global HIV Disease Coverage Forecast and Market 20
Post# of 301275
Dublin, May 11, 2018 (GLOBE NEWSWIRE) -- The "HIV Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering. The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS). Market Snapshot
- B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
- TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
- HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
- Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
- B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.
Key Topics Covered: Forecast: HIV
- Overview
- Executive Summary
- Market Dynamics
- Forecast And Future Trends
- Market Definition And Methodology
- Primary Research Methodology
- Bibliography
- Product Profile: Atripla
- Product Profile (Late Stage): B/F/Taf
- Product Profile: Complera
- Product Profile (Late Stage): Dor/3Tc/Tdf
- Product Profile: Descovy
- Product Profile: Genvoya
- Product Profile: Isentress
- Product Profile: Juluca
- Product Profile: Odefsey
- Product Profile: Prezista Franchise
- Product Profile: Reyataz Franchise
- Product Profile: Stribild
- Product Profile: Symtuza
- Product Profile: Tivicay
- Product Profile (Late Stage): Tivicay/Epivir
- Product Profile: Triumeq
- Product Profile: Truvada
- Product Profile (Late Stage): Cabotegravir/Rilpivirine
- Product Profile (Late Stage): Fostemsavir
Treatment: HIV
- Overview
- Primary Research Methodology
- Disease Definition And Diagnosis
- Patient Segmentation
- Current Treatment Options
- Treatment Guidelines
- Prescribing Trends
- Unmet Needs In HIV
- Impact Of Generics
Epidemiology: HIV
- Overview
- Executive Summary
- Disease Background
- Sources And Methodology
- Forecast: HIV
- Epidemiologist Insight
- Strengths And Limitations
- Appendix: Additional Sources
- Bibliography
Marketed Drugs: HIV
- Overview
- Executive Summary
- Product Overview
- Product Profile: Atripla
- Product Profile: Complera
- Product Profile: Descovy
- Product Profile: Genvoya
- Product Profile: Isentress
- Product Profile: Juluca
- Product Profile: Odefsey
- Product Profile: Prezista Franchise
- Product Profile: Reyataz Franchise
- Product Profile: Stribild
- Product Profile: Symtuza
- Product Profile: Tivicay
- Product Profile: Triumeq
- Product Profile: Truvada
Pipeline: HIV
- Overview
- Executive Summary
- Clinical Pipeline Overview
- Product Profile (Late Stage): B/F/Taf
- Product Profile (Late Stage): Dor/3Tc/Tdf
- Product Profile (Late Stage): Tivicay/Epivir
- Product Profile (Late Stage): Cabotegravir/Rilpivirine
- Product Profile (Late Stage): Fostemsavir
For more information about this report visit https://www.researchandmarkets.com/research/4...l_hiv?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: HIV/AIDS Drugs
(0)
(0)